Clinical trials: Anticoagulants
Heart Failure
Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)
Evaluation of the risk factors associated with Heart Failure (HF) worsening (measured by hospitalizations and emergency visits because of HF exacerbations) in Spanish patients with Atrial Fibrilation and HF treated with…
- Trial name
- FARAONIC (NCT03455439)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Spain
- Volunteers
- 552 people
- Sponsor
- Bayer
Obscure Gastrointestinal Bleeding, Iron-Deficiency Anemia
Endoscopic Evaluation for Iron Deficiency Anemia in Patients on Antithrombotic Therapy
This is a single-center, randomized pilot study evaluating the feasibility and safety of two management strategies for patients on antithrombotic therapy who present with obscure gastrointestinal bleeding (OGIB).
- Conditions
- Obscure Gastrointestinal Bleeding, Iron-Deficiency Anemia, Antithrombotic Therapy
- Trial name
- BEACON-IDA (NCT07089030)
- Testing
- Standard endoscopic evaluation, Conservative Medical Management
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Centre intégré universitaire de santé et de services sociaux de la Mauricie-et-du-Centre-du-Québec
Cervical Artery Dissection, Carotid Artery Dissection
To Determine the Feasibility of a Clinical Trial Comparing Anticoagulants Versus Antiplatelets in the Acute Treatment of Patients With Cervical Artery Dissection
This is a feasibility study to determine if a sufficient number of patients can be recruited throughout the United Kingdom and whether sufficient endpoints can be generated for a full scale therapeutic trial of anticoagulants…
- Conditions
- Cervical Artery Dissection, Carotid Artery Dissection, Vertebral Artery Dissection, Stroke
- Trial name
- CADISS (NCT00238667)
- Testing
- Antiplatelet (Aspirin, Dipyridamole, clopidogrel), Anticoagulant (Unfractionated Heparin, LMW Heparin, Warfarin)
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- St George's, University of London
Atrial Fibrillation, Stroke
Intention to Prescribe/Take OAC Depending on the Number of Risk Diagrams , and Period for the Estimation of the Risk.
Randomized study concerning the effect of the number of risk diagrams (with treatment +/- without treatment), the period of stroke risk estimation (one year or five years) and the target of prescription (the patient with atrial…
- Trial name
- NCT02746107
- Testing
- decision aid
- Where
- Romania
- Volunteers
- 968 people
- Sponsor
- Cristian Baicus
Atrial Fibrillation
Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Factor Xa Non-vitamin-K Oral Anticoagulants (NOACs) vs. Phenprocoumon
Existing real-world studies have provided evidence that novel oral anticoagulants (NOACs) in general and rivaroxaban in particular are more effective and at least as safe as warfarin in non-valvular atrial fibrillation (NVAF)…
- Trial name
- ReLoaDeD (NCT03563937)
- Testing
- Phenprocoumon, Apixaban, Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Germany
- Volunteers
- 64,920 people
- Sponsor
- Bayer
Thrombosis
Pharmacogentic Screening of Coumarine Based Oral Anticoagulant Using Next Generation Seguencer
As drug response is a complex trait in the majority of cases using an optimal starting dose for an individual may reduce the time taken to reach a stable INR, and reduce the risk of having either a high INR (with a risk of…
- Trial name
- NCT03180567
- Testing
- Genetic Mutations
- Where
- Egypt
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tanta University
DOAC Eligible Subjects
Direct Oral Anticoagulant Assay Detection & Classification Study for the TEG 6S System
Observational trial to evaluate the effectiveness of the TEG6s DOAC cartridge to detect and classify the presence of DOAC drugs in a subject.
- Trial name
- NCT02798328
- Testing
- TEG6s DOAC Cartridge
- Where
- 4 sites in United States
- Volunteers
- 385 people, healthy volunteers welcome
- Sponsor
- Haemonetics Corporation
Anticoagulants and Bleeding Disorders, Gastrointestinal Hemorrhage
Comparison of the Effect of Warfarin and Direct Oral Anticoagulants
In this study, it was aimed to compare the frequency of new oral anticoagulants and warfarin usage, and to reveal the rates of recurrent upper gastrointestinal bleeding among patients who applied to our hospital with upper…
- Trial name
- NCT06269302
- Where
- Turkey (Türkiye)
- Volunteers
- 346 people
- Sponsor
- Samsun Education and Research Hospital
Anticoagulants; Circulating, Hemorrhagic Disorder
Activates Charcoal for Patients Undergoing Invasive Procedure Delayed Due to Direct Oral Anticoagulants
This is a prospective, multicentric, randomized, open labeled superiority trial This study aims to evaluate the efficacy of oral activated charcoal for improving elimination of direct oral anticoagulants ( Rivaroxaban, Apixaban)…
- Trial name
- CACAOD (NCT02969746)
- Testing
- Activated Charcoal
- Where
- 6 sites in France
- Sponsor
- University Hospital, Angers
Surgery
Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery
Prospective, open-label clinical trial to evaluate the efficacy and safety of andexanet alfa patients who require urgent surgery that have been anticoagulated with the FXa (activated factor X) inhibitors.
- Trial name
- Annexa-S (NCT04233073)
- Testing
- andexanet alfa
- Where
- 56 sites in United States, Austria and 4 more
- Volunteers
- 10 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Atrial Fibrillation, Stroke
IMplementation of an RCT to imProve Treatment With Oral AntiCoagulanTs in Patients With Atrial Fibrillation
The purpose of this study is to use a decentralized claims database to determine whether education on stroke prevention in atrial fibrillation (AF) among AF patients and their providers can result in increased use of oral…
- Trial name
- IMPACT-AFib (NCT03259373)
- Testing
- Early Patient-Level and Provider-Level Educational Intervention, Delayed Provider-Level Educational Intervention
- Where
- 4 sites in United States
- Volunteers
- 64,666 people
- Sponsor
- Harvard Pilgrim Health Care
Circadian Variation in Anti-Factor Xa (Anti-FXa) Activity
Circadian Variation of Anti-Factor Xa in Hospitalized Trauma Patients
The purpose of this study is to determine whether a circadian rhythm exists in anti-FXa levels and AT3 activity in hospitalized trauma patients receiving low-molecular-weight heparin (LMWH) chemoprophylaxis
- Trial name
- NCT07856641
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- The University of Texas Health Science Center, Houston
Acute Coronary Syndrome, Percutaneous Coronary Intervention
Bivalirudin in Elderly Patients Undergoing Elective Percutaneous Coronary Intervention.
The study is an investigator-sponsored, prospective, multicenter, randomized, open-label study designed to compare efficacy and safety between bivalirudin and heparin in elderly patients with acute coronary syndrome undergoing…
- Conditions
- Acute Coronary Syndrome, Percutaneous Coronary Intervention, Aging, Anticoagulants and Bleeding Disorders
- Trial name
- NCT04046029
- Testing
- Bivalirudin, Heparin
- Where
- China
- Volunteers
- 240 people
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
Deep Vein Thrombosis, Venous Thromboembolism
Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study
This is the first evaluation of edoxaban in pediatric subjects. In this Phase 1 study, a single dose of edoxaban will be given to pediatric subjects who require anticoagulant therapy to see what the body does to the drug…
- Trial name
- NCT02303431
- Testing
- Edoxaban low dose, Edoxaban high dose
- Where
- 35 sites in United States, Canada and 7 more
- Volunteers
- 66 people
- Sponsor
- Daiichi Sankyo